OCA
ONC

OpenArc Corporate Advisory’s BeOne Medicines Ltd ONC Stock Holding History

OpenArc Corporate Advisory’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301K Buy
1,056
+267
+34% +$78.7K ﹤0.01% 627
2026
Q1 		$234K Buy
+789
New +$255K ﹤0.01% 636

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OpenArc Corporate Advisory's ONC Position: Q2 2026 in Review

OpenArc Corporate Advisory increased its BeOne Medicines Ltd (ONC) stake by 34% in Q2 2026, buying an estimated $78.7K and bringing the position to 1,056 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #627.

OpenArc Corporate Advisory first reported a position in ONC in Q1 2026 and has held it in 2 quarters since. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • OpenArc Corporate Advisory held 1,056 shares of BeOne Medicines Ltd worth $301K as of Q2 2026.
  • OpenArc Corporate Advisory bought 267 BeOne Medicines Ltd shares in Q2 2026, an estimated $78.7K.
  • BeOne Medicines Ltd made up ﹤0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #627 holding.
  • OpenArc Corporate Advisory first reported a position in BeOne Medicines Ltd in Q1 2026 and has held it in 2 quarters since.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.